Recorded Presentations from the NCCN 2025 Annual Congress: Hematologic Malignancies™

This congress focuses on updates to the NCCN Guidelines®, new and emerging therapeutic agents, and practical management strategies to ensure optimal patient outcomes.

Emerging Strategies in the Upfront Treatment of Hodgkin Lymphoma

Join Robert Chen, MD from City of Hope Comprehensive Cancer Center for this NCCN webinar presentation, Emerging Strategies in the Upfront Treatment of Hodgkin Lymphoma.

Archived NCCN Tumor Boards: Managing Unique Toxicities and Immune-Related Adverse Effects of Treatment for Hodgkin Lymphoma

There has been a major shift in the treatment paradigm of advanced CHL within the last several years, with antibody-drug conjugates and immune checkpoint inhibitors becoming an integral part of front-line treatment, allowing for reduction in toxicities such as pulmonary toxicity associated with b

NCCN Tumor Boards: Managing Unique Toxicities and Immune-Related Adverse Effects of Treatment for Hodgkin Lymphoma

There has been a major shift in the treatment paradigm of advanced CHL within the last several years, with antibody-drug conjugates and immune checkpoint inhibitors becoming an integral part of front-line treatment, allowing for reduction in toxicities such as pulmonary toxicity associated with b

Recorded Presentation from Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma

With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, un

The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma
The treatment landscape for relapsed/refractory Hodgkin lymphoma has changed significantly in recent years with the incorporation of novel agents such as brentuximab vedotin and the checkpoint inhibitors nivolumab or pembrolizumab. Second-line and subsequent therapy decisions are complex and must take into account multiple factors, such as use of novel agents in the frontline setting and the potential unique toxicities of novel agents.
Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma

With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, un

What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?
Novel agents such as antibody-drug conjugates and immune checkpoint inhibitors have become part of front-line treatment recommendations for advanced stage classic Hodgkin lymphoma over the last several years, allowing for reduction in toxicities such as pulmonary toxicity associated with bleomycin and secondary cancer risk from agents such as procarbazine.
Advances in the Management of Classical Hodgkin Lymphoma
Advances in the management of Hodgkin lymphoma (HL) and development of more effective treatment options over the last few decades have led to improvements in 5-year survival rates, with HL considered to be among the most curable of malignancies with modern treatments.
ECHELON-1: Do Updated Results Change the First-Line Treatment of Stage III-IV Classical Hodgkin Lymphoma?
An awareness of the updated safety and efficacy results from the ECHELON-1 trial will help clinicians determine how to optimally incorporate BV-AVD regimen as fist-line therapy in appropriately selected patients with stage III-IV classical Hodgkin lymphoma.

Pages

Subscribe to RSS - Hodgkin Lymphoma